Muvalaplin and Olpasiran Show Promise in Lowering Lp(a) : vi

Oral muvalaplin lowered lipoprotein(a) in a phase 1 study, and injectable olpasiran did so in an extension of a phase 2 study, both with no adverse safety signals, researchers report.

Related Keywords

Boston , Massachusetts , United States , Amsterdam , Noord Holland , Netherlands , Australia , United Kingdom , Monash , South Australia , Melbourne , Victoria , American , Eli Lilly , Louise Bowman , Michellel Odonoghue , Stephenj Nicholls , University Of Oxford , European Society Of Cardiology , Harvard Medical School , Amgen , Medicines Company , American Heart Association Scientific Sessions , Monash University , Astrazeneca , Victoria Heart Institute , Boehringer Ingelheim , Novartis , European Society , New England Journal , New Amsterdam Pharma , Lipids , Ipid Management , Cv , Ardiovascular , Pcsk9 , Roprotein Convertase Subtilisin Kexin Type 9 , Grant , Heart , Low Ldl Cholesterol , Ypobetalipoproteinemia , Ow Low Density Lipoprotein Cholesterol , Apolipoproteins , Atherosclerosis , Body Mass Index Bmi , Cardiovascular Disease , Vd Cardiovascular Disease , Fatigue , Genetics , Hospitals , Imbalance , Interference , Lipoproteins , Liver , Genomi ,